Loading…
Employees: 3,908
Size Beijing Foyou Pharma (601089.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $455M, the 4083rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.69 on 6 Nov 2026.
Performance Over six months the shares fell 23.8%, against -13.1% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue grew 5.5% over the last twelve months (peer median -4.9%); the operating margin is 9.6% (peer median 4.4%).
Valuation It trades at 12.8× forward earnings against a peer median of 25.1× (2nd cheapest of 6).
Capital Return on invested capital runs 13.9 points above its cost of capital (6.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.61B | CN¥3.48B | CN¥3.42B | CN¥3.31B | CN¥3.21B |
| Revenue growth | — | +2% | +3% | +3% | — |
| Gross profit | CN¥2.29B | CN¥2.23B | CN¥2.25B | CN¥2.16B | CN¥2.15B |
| EBITDA | n/a | CN¥628M | CN¥575M | CN¥586M | CN¥514M |
| Net income | CN¥368M | CN¥469M | CN¥489M | CN¥489M | CN¥439M |
| Free cash flow | CN¥325M | -CN¥17.7M | CN¥311M | CN¥192M | CN¥527M |
| Capital expenditure | CN¥120M | CN¥397M | CN¥392M | CN¥366M | CN¥135M |
| Total debt | CN¥12.6M | CN¥25.8M | CN¥75.2M | CN¥124M | CN¥123M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 601089.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.7% | -11.4% | 5th highest of 20 |
| 6-month return | -23.8% | -13.1% | 4th lowest of 20 |
| Distance from 52-week high | -49.1% | -37.9% | 5th lowest of 20 |
| Revenue growth (TTM) | +5.5% | -4.9% | 9th highest of 21 |
| Operating margin | 9.6% | 4.4% | 7th highest of 21 |
| Forward P/E | 12.8× | 25.1× | 2nd cheapest of 6 |
| ROIC minus cost of capital | +13.9 pp | -1.6 pp | highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Foyou Pharma 601089.SS | China | $455M | -24% | +5% | 10% | 12.8× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | n/a | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | n/a | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | n/a | 23.7% | +28.2% |
| Evolus EOLS | United States | $449M | +7% | +14% | -7% | 27.4× | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $448M | +2% | +12% | 18% | n/a | n/a | n/a |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | n/a | 7.1% | +1.3% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | n/a | 2.5% | -1.3% |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | n/a | 33.5% | -0.9% |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 31.1× | 26.6% | +8.0% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | n/a | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | n/a | 46.5% | -1.5% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | n/a | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $442M | +2% | +11% | 11% | n/a | 6.5% | +15.3% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 11.1× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 25.1× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | n/a | -8.9% | -3.4% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | n/a | -4.9% | +0.7% |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 21.0× | 5.7% | +3.3% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | n/a | n/a | n/a |